representative of MM patients. Bone marrow mononuclear cells were isolated by Ficoll-Hypaque sedimentation and extracted DNA was modified for MSP by bisulfite using the CpGenome TM DNA Modification Kit (Intergen, Purchase, USA). SOCS-1 gene promoter regions were amplified with DNA methylated and unmethylated specific primers as previously described. 5 A total of 51 samples of MM bone marrow cells were analyzed by MSP. Selective methylation of SOCS-1 gene was found in 38/51 patients (74.5%). No correlation could be made between SOCS-1 gene methylation and gender, age, isotype, level of M-component, stage of the disease, serum levels of albumin, creatinin, calcium, b2-microglobulin, LDH, C-reactive protein, or response to treatment. Overall survival was not significantly different between patients with methylated and unmethylated SOCS-1 gene (P ¼ 0.58), median survival being estimated at 27.1 months (95% CI, 14.4-39.8) and 23.1 months (95% CI, 17.3-28.9), respectively ( Figure 1) .
Methylation of SOCS-1 gene is frequent in MM, occurring at frequencies of 75% in our series. It may represent an important epigenetic event in the pathogenesis of MM. However, SOCS-1 gene methylation does not seem to influence the clinical outcome of MM patients. [1] [2] [3] [4] [5] This chromosomal abnormality is most often detected by conventional cytogenetic methods as a tandem duplication of chromosome band 21q22 or as marker chromosomes of unknown origin. [1] [2] [3] [4] [5] However, in B-cell precursor ALL, various numerical and structural abnormalities of chromosome 21 can lead to multiple copies of AML1. Among the abnormalities are trisomy or tetrasomy 21 (which can be the sole abnormality or associated with high hyperdiploidy 450 chromosomes), and isochromosomes 21q or ider(21q)t(12;21). Therefore, more stringent molecular methods of detection are needed to specifically identify AML1 amplification.
S Depil
Before we attempted to confirm that amplification of band 21q22, including AML1, is characteristic of an emerging ALL subtype, we developed a FISH-based inclusion criteria for detection of AML1 amplification/over-representation by FISH. These consisted of detection of four or more AML1 signals in interphase nuclei, and the colocalization of three or more signals on the same metaphase chromosome; when no mitotic cells were obtained, the presence of an AML1 amplification was considered to have occurred if FISH resulted in five or more AML1 signals in interphase nuclei. It is generally accepted that up to four to five copies of a gene the term of over-representation should be prefered, and above that number amplification can be used. On the basis of these inclusion criteria, we report here 16 pediatric patients with B-cell precursor ALL and amplification/over-representation of band q22 including AML1 (Table 1) .
Patients were referred to pediatric centers in France (Centre Hospitalier Universitaire CHU Brest; CHU Nantes; CHU Nice, In five of the seven cytogenetic laboratories involved in this study, the detection by FISH of the t(12;21) was performed prospectively for the last 2 years on all newly diagnosed B-cell ALL cases. In the remaining two centers, FISH using a probe specific to the TEL-AML1 fusion gene is usually performed to confirm positive PCR results, or when chromosome 12p or chromosome 21 abnormalities are suspected.
The LSI TEL-AML1 ES dual-color translocation probe (Vysis, Downer's Grove, IL, USA and Adgenix, Voisin-Le-Bretonneux, France) was used by all laboratories. This probe is a mixture of the LSI TEL probe labeled with Spectrum Green and the AML1 probe labeled with Spectrum Orange. The approximately 500 kb AML1 probe spans the entire AML1 gene and contains genomic DNA centromeric to this gene, which is located at 21q22. The probe was used according to the manufacturer's recommendations. Briefly, slides were denatured at 751C for 2 min; probes were denatured at the same temperature for 5 minutes. Subsequently, the two were hybridized overnight at 371C. Hybridization signals were evaluated by using DAPI/FITC/rhodamine triple-band pass filter sets.
According to our FISH inclusion criteria, we found that the leukemic cells from the 16 pediatric patients with newly diagnosed B-cell precursor ALL had multiple copies of band q22 including AML1. The AML1 copy number ranged from four to more than 10 per interphase nuclei or metaphase chromosomes (Table 1 and Figure 1 ). Multiple 21q22 and AML1 signals were clustered in an area within the interphase nuclei in most cases (Figure 1 , panels A-C), and were consistently located on the same metaphase chromosome. All cases in this study had high percentages of cells with the AML1 amplification; in fact, almost all of the leukemic cells contained this amplification, a finding consistent with the hypothesis that this is a major oncogenic event. Two signals specific for the TEL probe were observed in all cases.
When conventional cytogenetic findings were evaluated, we identified four ploidy patterns (Table 1) : pseudodiploid (n ¼ 8), low hyperdiploid (from 47 to p50 chromosomes) (n ¼ 3), high hyperdiploid 450 chromosomes (n ¼ 2), and diploid (n ¼ 1). No karyotype was determined for two additional cases because of the absence of mitotic cells; no DNA index was available for these patients. All patients in the pseudodiploid and low hyperdiploid groups had marker chromosomes, numerical or structural abnormalities of chromosome 21 such as add(21q), del(21q), trp(21q), qdq(21q), or both marker chromosomes and chromosome 21 abnormalities. FISH with whole-chromosome painting probes showed that these marker chromosomes originated from chromosome 21 (data not shown). FISH using the locus-specific AML1 probe resulted in the appearance of several signals on a single chromosome ( Figure 1, panel d) . Conventional cytogenetics revealed various structural or numerical chromosome abnormalities were also present in most cases. Among the patients in the high hyperdiploidy group, at least two did not have tetrasomy 21 as indicated by conventional cytogenetics. This finding suggests that the 21q22 amplification could be a functional equivalent of tetrasomy 21 in high hyperdiploid ALL. Moreover, the marker chromosome in which AML1 was amplified was duplicated in patient 13 ( Figure 1, panel b) . However, caution should be taken in this interpretation as possible asymmetry of replication and the presence of twin/double spots cannot be ruled out in some of these cases. The interpretation of cases with normal karyotypes and 21q22 amplification is equivocal; probably the leukemic cells are not dividing; alternatively the amplification could be cryptic. In all cases, conventional cytogenetics, FISH and/or molecular analyses did not detect recurrent translocations, including the t(12;21), t(9;22), and t(4;11), in association with AML1 amplification. When the major clinical and biological features of the pediatric patients with ALL and multiple copies of 21q22 including AML1 were analyzed, particular features appeared to be associated with the pseudodiploid and low hyperdiploid groups. Within these groups (n ¼ 11), the median age was 13 years (range, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] ; in contrast, the two patients in the high hyperdiploid group were only 5 and 6 years old. The peripheral white blood cells (WBCs) counts at diagnosis were low (median, 6.6 Â 10 3 /ml; range, 0.9-18). In comparison, the median age of patients with B-cell precursor ALL in the FRALLE 93 trial (n ¼ 1195) was 4.7 years (range, 0.1 to 19 years) and the median WBC count was 9.5 Â 10 3 /ml (range, 0.3-1350). 6 Immunological analysis using a standard antibody panel revealed common CD10-positive B-cell precursor phenotype in all cases. Furthermore, six cases were early pre-B (Cm . We observed no particular association of 21q22 amplification with immunophenotype. Remission was achieved in the 14 patients for whom clinical records were available. The median follow-up period was 21 months (range, 0.5 to 127). Although two of the patients relapsed, one is in second remission, and the other is in third remission.
Using our FISH criteria, we evaluated cases from the literature and identified 14 additional pediatric cases with ALL and amplification or over-representation of 21q22, including eight cases with pseudodiploidy or low hyperdiploidy. The clinical and biological features of these eight patients were consistent with our findings, including older age (median, 11.5 years) and low WBC counts (median, 4.3 Â 10 3 /ml) ( Table 1) . The similarity in the characteristics of these cases suggests that amplification of 21q22, including AML1, within pseudodiploid or low hyperdiploid leukemic cells represents an emerging subtype of B-cell precursor ALL, potentially distinct from the subtypes characterized by the t(12;21) and other recurrent chromosome abnormalities. A systematic prospective screening of AML1 amplification in ongoing ALL clinical trials is now necessary to determine the frequency and the prognostic value of this cytogenetic abnormality.
It is unknown what genes are the targets of the amplification process. Besides AML1 there is evidence that 21q22.13-22.2 and subtelomeric 21q band are also amplified (V Najfeld, data not shown), and other gene(s) at 21q22 might be oncogenic target(s) activated by amplification. Genomic and expression analyses should help to elucidate the oncogenic mechanisms associated with multiple copies of 21q22 and AML1 amplification in this newly recognized molecular cytogenetic subgroup of ALL. 
TO THE EDITOR
We agree with Kussick et al 1 that not every case of T-cell leukemia is easily classifiable. However, the only way forward in establishing the correct diagnosis and improving the WHO classification is to be able to define new disease entities. Currently, there are no data in the literature, nor in their letter, to support the view that there is a Tcell leukemia that should be classified as T-cell chronic lymphocytic leukemia (T-CLL). Historically, the term 'T-CLL' was first used by Brouet et al 2 in 1975, when they described patients who would now be considered largely to be part of T-cell large granular lymphocytic (T-LGL) leukemia and a few cases that we now call T-prolymphocytic leukemia (T-PLL). A large number of subsequent reports and data emerging from the literature have allowed us to separate T-LGL leukemia from T-PLL. 3, 4 Since then, there has been no clear evidence that a third entity, T-CLL, as proposed by Kussick et al, 1 indeed exists. We recognize that in T-PLL there is a degree of morphological heterogeneity, which is already considered in the WHO classification 5 and in our experience. [3] [4] [5] [6] Therefore, the classification of T-cell malignancies should not be based purely on the morphological criteria but substantiated by the underlying molecular/genetic features as well as clinical manifestations. Not all T-PLL cases have circulating cells with the morphology of prolymphocytes as in the classic 1974 description by Galton, which is more applicable to B-cell PLL. Although the term 'prolymphocyte' may not be ideal to use in this condition, it has been retained for historical reasons and indeed, provided everybody understands the disease behavior and what this term defines, this should not be an issue.
On reviewing the representative case #1 reported by Kussick et al, 1 it is likely that this represents an example of small-cell variant T-PLL, as defined by the WHO classification and as seen by us in many patients; [3] [4] [5] [6] the cells in the black and white illustration appear typical, with cytoplasmic blebs, although a nucleolus is not prominent, a feature that is common in the small-cell T-PLL variant. The phenotype CD4+, CD7+, CD8À would fit very well with T-PLL. Unfortunately, the key investigation, chromosome analysis and/or overexpression of TCL-1 or mutational analysis for ATM -features also characteristic of T-PLL, 7-9 -have not been performed. A second case in which no details are given does not add weight to their argument.
We would also disagree that there is a conflict between the REAL and the WHO classifications. 5, 10 The REAL was an attempt to start grouping cases into disease entities; there was no clear separation of cases within the mature T-cell leukemias, but since that timeextensive work has been carried out and a consensus reached between pathologists and clinicians. The very high WBC of case #1, 500 Â 10 9 /l, fits with the aggressive nature of the disease. We are not given any details of follow-up but, in our experience, without appropriate treatment, the median survival of T-PLL is 7 months. 3 We feel that there is no need to go back to old classification systems in which no clear description of disease entities was given; this will not serve any useful purpose for clinicians dealing with these conditions. In particular, since Campath-1H (Alemtuzumab) appears to be the treatment of choice in T-PLL, 11,12 the correct diagnosis of this disease becomes clinically relevant.
Although we recognize that there is a degree of morphological heterogeneity in T-PLL, the data on cytogenetics and molecular genetics are overwhelming, with 90% of patients having inversion 14(q11;q32) and abnormalities of chromosome 8 in 80%. 7, 9 Further advances will, of course, be welcome, but when one undertakes such studies, there is a need to investigate the patients adequately in every aspect -morphology, immunophenotype, cytogenetics and clinical manifestations -and then submit the material to further molecular analysis, for example, gene profiling. Such advances may or may not define new disease entities but will refine the diagnostic criteria and point to genes relevant to pathogenesis. In these and other conditions such as B-cell CLL, the way to progress is to agree on the basic data and then move forward with the new information. 
